LACTOLOGY FOUNDATION

Methylatropine (ATC A03BB02) is a quaternary ammonium derivative of atropine used as a peripheral antimuscarinic agent for functional gastrointestinal disorders, with limited central nervous system penetration and restricted, older use in clinical practice. In lactating women, no direct human data exist, but by analogy with atropine and based on its poor oral bioavailability and low likelihood of significant transfer into breast milk, short-term, low-dose use is generally expected to carry a low risk for the breastfed infant, while prolonged or high-dose therapy should be avoided or closely monitored.wikipedia+5

Classification and chemical nature

Methylatropine (also known as methylatropinium or N‑methylatropinium) is classified in the ATC system under A03BB02, within “belladonna alkaloids, semisynthetic, quaternary ammonium compounds” used for functional gastrointestinal disorders. It is the quaternary ammonium salt of atropine (structurally related to atropine methylnitrate), highly polar and permanently charged, which limits its ability to cross lipid membranes and the blood–brain barrier.medbox.iiab+6

Mechanism of action

Methylatropine acts as a potent competitive antagonist at muscarinic acetylcholine receptors (M‑receptors), with very high affinity in in vitro assays. By blocking parasympathetic cholinergic transmission, it reduces smooth muscle tone and motility in the gastrointestinal tract and inhibits secretions, leading to antispasmodic and antisecretory effects. Because of its quaternary ammonium structure, its effects are predominantly peripheral, with minimal central anticholinergic activity compared to atropine.drugcentral+4

Indications and therapeutic use

Historically, methylatropine was introduced for the relief of gastrointestinal spasms and functional disorders such as pylorospasm, because its polar nature reduced central toxicity compared with atropine. In modern practice, its use is limited, and other antispasmodics (e.g. butylscopolamine, other A03BB agents) are often preferred, but it may still appear in formularies for functional gastrointestinal complaints. On some national reference sites, methylatropine is simply described as a belladonna-derived medicine available by prescription, with dosing left to the prescriber’s judgment.medpedia.framar+3

Pharmacokinetics and disposition

Due to its quaternary ammonium structure, methylatropine is poorly lipid‑soluble and has limited oral absorption and tissue penetration, particularly across the blood–brain barrier. Systemic bioavailability after oral administration is lower than that of atropine, and distribution is largely confined to peripheral compartments, which reduces central nervous system adverse effects but not peripheral anticholinergic toxicity. Like other atropine derivatives, it is expected to undergo hepatic metabolism and renal excretion, although detailed human pharmacokinetic data for methylatropine are scarce.sciencedirect+3

Toxicology and adverse effects

The toxicological profile of methylatropine mirrors that of other antimuscarinic agents, with dose-dependent anticholinergic effects on multiple organ systems. Common adverse reactions include dry mouth, decreased sweating, tachycardia, blurred vision, urinary retention, and constipation, reflecting blockade of muscarinic receptors in exocrine glands, heart, eye, and smooth muscle. At high doses or in susceptible individuals, severe toxicity can manifest as hyperthermia, pronounced tachycardia, paralytic ileus, acute urinary retention, and, despite limited CNS penetration, potential confusion or agitation in vulnerable patients.prescriberpoint+3

Contraindications and precautions

Standard contraindications align with those for other antimuscarinics: known hypersensitivity to methylatropine or excipients, narrow‑angle glaucoma, obstructive uropathy (e.g. prostatic hypertrophy), mechanical gastrointestinal obstruction, and severe ulcerative colitis with risk of toxic megacolon. Caution is warranted in patients with cardiovascular disease (tachyarrhythmias, ischemic heart disease, hypertension) and in those with autonomic neuropathy, given the risk of exacerbating hemodynamic instability. National reference information emphasizes that patients should not use methylatropine in case of hypersensitivity and that dosing must be individualized by a physician, with prescription-only access.medpedia.framar+2

Drug interactions

Methylatropine may potentiate the anticholinergic burden when combined with other antimuscarinic drugs such as tricyclic antidepressants, certain antihistamines, antipsychotics, and other belladonna alkaloids. It can also antagonize the effects of prokinetic agents that rely on cholinergic pathways and may interfere with the response to cholinesterase inhibitors in myasthenia gravis. Extrapolating from atropine data, concomitant use with monoamine oxidase inhibitors has been discouraged due to theoretical risks of blood pressure destabilization, although robust data for methylatropine are lacking.drugcentral+2

Toxicity in overdose

In overdose, methylatropine produces a classic peripheral anticholinergic toxidrome: dry, flushed skin, hyperthermia, mydriasis with photophobia, tachycardia, ileus, urinary retention, and reduced or absent sweating. Central manifestations (delirium, hallucinations, seizures) are less prominent than with atropine because of poorer CNS penetration, but they cannot be excluded at very high doses or in compromised blood–brain barrier conditions. Management is supportive, with attention to airway, temperature control, and cardiovascular status; physostigmine may be considered in severe, life‑threatening anticholinergic toxicity, although experience with methylatropine specifically is limited and should follow toxicology consultation.cumming.ucalgary+4

Use during pregnancy

There are no robust, controlled data on methylatropine use in human pregnancy, and safety must be inferred from atropine and related agents. Systemic atropine has not been conclusively linked to major teratogenic effects, but ophthalmic formulations highlight the lack of adequate pregnancy data and recommend use only if the benefit justifies the potential risk. Given the limited systemic absorption and short courses typical for gastrointestinal spasm treatment, occasional use of methylatropine in pregnancy is unlikely to be highly teratogenic, but routine or prolonged use is best avoided when safer alternatives exist.wikipedia+1

Lactation: transfer into milk and infant exposure

Almost all drugs appear in human breast milk to some degree, but the extent and clinical significance depend on maternal dose, pharmacokinetics, and infant oral bioavailability. No specific LactMed or clinical case reports were identified for methylatropine, so lactation risk assessment relies on its physicochemical properties and extrapolation from atropine and similar quaternary antimuscarinic agents.infantrisk+3

Because methylatropine is a quaternary ammonium compound with poor lipid solubility and limited oral absorption, any drug that enters breast milk is likely to have low oral bioavailability in the infant, reducing systemic exposure. By analogy, systemic exposure of infants to low oral doses in the mother is expected to be small, particularly with short-term use, suggesting a low risk of significant anticholinergic toxicity in healthy term infants.medbox.iiab+3

Potential effects on the breastfed infant

Theoretical infant adverse effects include anticholinergic manifestations such as decreased gastrointestinal motility (constipation, reduced stool frequency), urinary retention, dry mouth, and, at higher exposures, tachycardia and temperature dysregulation. However, the combination of limited maternal systemic exposure (for usual doses), restricted transfer into milk, and low infant oral absorption makes clinically important toxicity unlikely at therapeutic maternal doses and short durations. As with other anticholinergic agents, premature infants or those with underlying gastrointestinal or urinary tract disorders may be more susceptible to even modest exposures and warrant heightened caution.cumming.ucalgary+4

Potential effects on lactation and milk production

Anticholinergic drugs can, in theory, reduce secretions, but the primary determinants of lactation are prolactin and oxytocin pathways, not directly mediated by muscarinic receptors. Evidence from other cardiovascular and antispasmodic agents indicates that most medications produce only minimal or no clinically significant impact on milk production when used at therapeutic doses. For methylatropine, no reports describe suppression of lactation, and any effect on milk volume is likely to be negligible with short-term or intermittent use.ncbi.nlm.nih+2

Risk–benefit assessment in breastfeeding

In breastfeeding women with functional gastrointestinal disorders, non‑pharmacological measures and better-characterized agents should be prioritized where feasible. If methylatropine is considered necessary (e.g. lack of response or intolerance to alternatives), short-term, low-dose therapy in a healthy term infant is probably compatible with continued breastfeeding, provided the infant is observed for signs of anticholinergic effects (reduced feeding, constipation, unusual irritability or lethargy). In high-risk contexts (preterm infants, prolonged high-dose maternal therapy, polypharmacy with other anticholinergics), individualized risk assessment using specialized lactation resources (e.g. LactMed, InfantRisk, MotherToBaby) is recommended.mothertobaby+3

Practical monitoring recommendations

When methylatropine must be used during lactation, clinicians should ensure the lowest effective dose and shortest possible duration, and avoid combination with other anticholinergic drugs where possible. Parents should be counseled to monitor the infant for decreased feeding, reduced stool frequency, dry mouth, decreased urine output, or unusual behavior changes, and to seek medical attention if such signs appear. Regular follow-up is advisable if treatment extends beyond a few days, especially in neonates and infants with comorbidities.infantrisk+2

Summary of lactation safety (expert-oriented)

Based on physicochemical properties, expected pharmacokinetics, and extrapolation from related agents, methylatropine would be reasonably classified as a drug with low expected risk in breastfeeding when used intermittently and at standard doses in healthy term infants, but with insufficient direct evidence to assign a definitive safety category. In the absence of direct human milk level data, cautious, case-by-case use is warranted, avoiding prolonged or high-dose regimens and favoring better-studied alternatives when available.ncbi.nlm.nih+4